Long-term compliance and results of intravesical botulinum toxin A injections in male patients.

Détails

ID Serval
serval:BIB_11593BC6741B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
Périodique
Neurourology and urodynamics
Auteur(s)
Rahnama'i M.S., Marcelissen TAT, Brierley B., Schurch B., de Vries P.
ISSN
1520-6777 (Electronic)
ISSN-L
0733-2467
Statut éditorial
Publié
Date de publication
09/2017
Peer-reviewed
Oui
Volume
36
Numéro
7
Pages
1855-1859
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Intravesical injections with botulinum toxin A (BoNT-A) is an established treatment for patients with overactive bladder (OAB) symptoms. However, most studies have evaluated the efficacy of this treatment in women and report short-term results. In this study, we evaluated the long-term compliance of BoNT-A in a heterogeneous group of male patients.
This is a retrospective, single-centre study. We evaluated all male patients who have been treated with BoNT-A from 2004 until 2010 in a large teaching hospital. Patients received 100-300 U of onabotulinum toxin-A in 20 intravescial injections. Some patients received dose adjustment with repeated injections.
In total, 88 male patients were included. The mean follow-up was almost 6 years (69 months). Of all patients, 22 (25%) continued BoNT-A treatment at last follow-up (success). Of the patients who discontinued treatment, 35 had insufficient effect and 27 had tolerability issues (eg, urinary retention, self-catheterisation, voiding LUTS). Four patients abandoned treatment due to other reasons that were not related to BoNT-A. Of all patients, 24% had to use intermittent catheterisation (de novo) or indwelling catheters at some point during the follow-up.
In this real-life, heterogeneous cohort of men, the long-term compliance with BoNT-A was 25%. Patients with neurogenic OAB symptoms appear to have the best results in our study with 36% of patients who were still on active treatment during last follow-up. Intravesical BoNT-A can be an effective treatment for men with OAB symptoms. In our study, only 25% of patients continued treatment during long-term follow-up. Larger, prospective trials are needed to confirm these results.
Mots-clé
Administration, Intravesical, Adult, Aged, Aged, 80 and over, Botulinum Toxins, Type A/therapeutic use, Follow-Up Studies, Humans, Male, Medication Adherence, Middle Aged, Neuromuscular Agents/adverse effects, Patient Compliance, Postoperative Complications/drug therapy, Prostatectomy, Prostatic Neoplasms/surgery, Retrospective Studies, Transurethral Resection of Prostate, Treatment Outcome, Urinary Bladder, Neurogenic/complications, Urinary Bladder, Neurogenic/drug therapy, Urinary Bladder, Overactive/drug therapy, Urinary Bladder, Overactive/etiology, Urinary Retention/chemically induced, botox, botulinium toxine A, detrusor overactivity, male, men, overactive bladder syndrome, urgency
Pubmed
Web of science
Création de la notice
24/01/2017 19:37
Dernière modification de la notice
20/08/2019 13:38
Données d'usage